Project description
Improved vaccines for older age
The goal of the EU-funded ISOLDA project is to develop novel vaccines against viral diseases for older age by promoting virus-specific T cell responses targeting T cell immunosenescence and inflamm-ageing. An international consortium will assess the potential of immunomodulators, including kinase inhibitors licensed for other applications, to improve vaccine-induced immune responses. The best selected compounds will be tested using in vivo animal models for vaccination against viral diseases. As clinical proof of concept, researchers will focus on improving the efficacy of influenza vaccines applying a lead immunomodulator compound selected from the ex vivo and in vivo studies to the current vaccine formulations. ISOLDA aims to provide innovative solutions to the age-related reduced efficacy in current preventive vaccines against viral infections for the increasing population of older adults.
Fields of science
Programme(s)
Funding Scheme
RIA - Research and Innovation action
Coordinator
30559 Hannover
Germany
See on map
Participants (6)
31008 Pamplona
See on map
3015 GD Rotterdam
See on map
20359 Hamburg
See on map
28006 Madrid
See on map
90133 Palermo
See on map
3605 LT Maarssen
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.